# Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate

> **NCT02313922** · PHASE4 · COMPLETED · sponsor: **Zhejiang University** · enrollment: 466 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** etanercept combined with methotrexate or etanercept combined with placebo

## Key facts

- **NCT ID:** NCT02313922
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 466 (ACTUAL)
- **Last updated:** 2018-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02313922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02313922, "Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02313922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*